KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer

Daniel P. Petrylak; Raffaele Ratta; Rustem Gafanov; Gaetano Facchini; Josep M. Piulats; Gero Kramer; Thomas W. Flaig; Sreenivasa R. Chandana; Ben Li; Joseph Burgents; Karim Fizazi

doi:10.2217/fon-2020-1133

KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer

Daniel P. Petrylak, Raffaele Ratta, Rustem Gafanov, Gaetano Facchini, Josep M. Piulats, Gero Kramer, Thomas W. Flaig, Sreenivasa R. Chandana, Ben Li, Joseph Burgents, Karim Fizazi

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

27 Citations (Scopus)

Résumé

Despite recent advances, treatment options for men with metastatic castration-resistant prostate cancer (mCRPC) progressing after next-generation hormonal agents (NHAs) are limited and provide only modest survival benefit. Thus, an unmet need remains for mCRPC patients after treatment with targeted endocrine therapy or NHA therapy. Pembrolizumab, a humanized monoclonal antibody for PD-1, has been found to have activity as monotherapy in patients with mCRPC and as combination therapy in a Phase Ib/II study with docetaxel and prednisone/prednisolone for patients previously treated with enzalutamide or abiraterone acetate. The aim of the randomized, double-blind, Phase III KEYNOTE-921 study is to evaluate the efficacy and safety of pembrolizumab plus docetaxel in patients with mCRPC who were previously treated with an NHA.

langue originale	Anglais
Pages (de - à)	3291-3299
Nombre de pages	9
journal	Future Oncology
Volume	17
Numéro de publication	25
Les DOIs	https://doi.org/10.2217/fon-2020-1133
état	Publié - 1 sept. 2021

Accès au document

10.2217/fon-2020-1133

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{0d973247ffe04046802a13b4b8490cae,

title = "KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer",

abstract = "Despite recent advances, treatment options for men with metastatic castration-resistant prostate cancer (mCRPC) progressing after next-generation hormonal agents (NHAs) are limited and provide only modest survival benefit. Thus, an unmet need remains for mCRPC patients after treatment with targeted endocrine therapy or NHA therapy. Pembrolizumab, a humanized monoclonal antibody for PD-1, has been found to have activity as monotherapy in patients with mCRPC and as combination therapy in a Phase Ib/II study with docetaxel and prednisone/prednisolone for patients previously treated with enzalutamide or abiraterone acetate. The aim of the randomized, double-blind, Phase III KEYNOTE-921 study is to evaluate the efficacy and safety of pembrolizumab plus docetaxel in patients with mCRPC who were previously treated with an NHA.",

keywords = "metastatic castration-resistant prostate cancer, pembrolizumab",

author = "Petrylak, {Daniel P.} and Raffaele Ratta and Rustem Gafanov and Gaetano Facchini and Piulats, {Josep M.} and Gero Kramer and Flaig, {Thomas W.} and Chandana, {Sreenivasa R.} and Ben Li and Joseph Burgents and Karim Fizazi",

note = "Publisher Copyright: {\textcopyright} 2021 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.",

year = "2021",

month = sep,

day = "1",

doi = "10.2217/fon-2020-1133",

language = "English",

volume = "17",

pages = "3291--3299",

journal = "Future Oncology",

issn = "1479-6694",

number = "25",

}

TY - JOUR

T1 - KEYNOTE-921

T2 - Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer

AU - Petrylak, Daniel P.

AU - Ratta, Raffaele

AU - Gafanov, Rustem

AU - Facchini, Gaetano

AU - Piulats, Josep M.

AU - Kramer, Gero

AU - Flaig, Thomas W.

AU - Chandana, Sreenivasa R.

AU - Li, Ben

AU - Burgents, Joseph

AU - Fizazi, Karim

PY - 2021/9/1

Y1 - 2021/9/1

N2 - Despite recent advances, treatment options for men with metastatic castration-resistant prostate cancer (mCRPC) progressing after next-generation hormonal agents (NHAs) are limited and provide only modest survival benefit. Thus, an unmet need remains for mCRPC patients after treatment with targeted endocrine therapy or NHA therapy. Pembrolizumab, a humanized monoclonal antibody for PD-1, has been found to have activity as monotherapy in patients with mCRPC and as combination therapy in a Phase Ib/II study with docetaxel and prednisone/prednisolone for patients previously treated with enzalutamide or abiraterone acetate. The aim of the randomized, double-blind, Phase III KEYNOTE-921 study is to evaluate the efficacy and safety of pembrolizumab plus docetaxel in patients with mCRPC who were previously treated with an NHA.

AB - Despite recent advances, treatment options for men with metastatic castration-resistant prostate cancer (mCRPC) progressing after next-generation hormonal agents (NHAs) are limited and provide only modest survival benefit. Thus, an unmet need remains for mCRPC patients after treatment with targeted endocrine therapy or NHA therapy. Pembrolizumab, a humanized monoclonal antibody for PD-1, has been found to have activity as monotherapy in patients with mCRPC and as combination therapy in a Phase Ib/II study with docetaxel and prednisone/prednisolone for patients previously treated with enzalutamide or abiraterone acetate. The aim of the randomized, double-blind, Phase III KEYNOTE-921 study is to evaluate the efficacy and safety of pembrolizumab plus docetaxel in patients with mCRPC who were previously treated with an NHA.

KW - metastatic castration-resistant prostate cancer

KW - pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85113398819&partnerID=8YFLogxK

U2 - 10.2217/fon-2020-1133

DO - 10.2217/fon-2020-1133

M3 - Article

C2 - 34098744

AN - SCOPUS:85113398819

SN - 1479-6694

VL - 17

SP - 3291

EP - 3299

JO - Future Oncology

JF - Future Oncology

IS - 25

ER -